Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Flurbiprofen cataplasm

A flurbiprofen and poultice technology, applied in the field of flurbiprofen poultices, can solve the problems of large side effects, analgesic and anti-inflammatory effects in difficult areas, large dosage and the like

Inactive Publication Date: 2017-09-15
北京茗泽中和药物研究有限公司
View PDF4 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, when the traditional oral administration method is used to treat pain caused by trauma and inflammation of joints, soft tissues, and muscles, it needs to take a large amount of medicine, resulting in relatively large side effects, and the drug release cannot be controlled, making it difficult to provide lasting and effective analgesia on the affected area. Anti-inflammatory effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Flurbiprofen cataplasm
  • Flurbiprofen cataplasm
  • Flurbiprofen cataplasm

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Pharmacological Example 1 In Vitro Release Experiment

[0021] According to the method provided in the third method (paddle and disk method, used for transdermal patch) in the second appendix XD of the Chinese Pharmacopoeia 2010 edition, the emergency release of the patch obtained in Examples 1 to 6 is measured . The specific method is as follows

[0022] In the test, physiological saline was used as the release medium, and the release medium was added into the dissolution cup, pre-warmed to (32±0.5°C) to remove the protective layer of the cataplasm, cut into a size of 2.5cmx7.5cm, and put it flat into a dialysis bag (molecular weight cut-off 14,000 ), with the release side facing up, placed between two layers of discs, so that the edges of the disc clamp the two ends of the dialysis bag, and then wrap and fix with rubber bands to fix the disc. At 10min, 20min, 30min, 45min, 60min, 90min, 2h, 2.5h, 3h and 4h, 6mL samples were taken from the dissolution vessel respecti...

Embodiment 2

[0023] Pharmacological embodiment 2, in vitro transdermal experiment

[0024] Using the modified Franz diffusion cell method, the abdominal skin of isolated 3-month-old rats was used as a barrier, and the cataplasm patch prepared in Examples 1-6 and Comparative Examples 1-6 was used to conduct an in vitro transdermal test. The specific experimental method is:

[0025] After 3-month-old healthy rats were anesthetized and killed, the abdominal hair was removed with scissors, the undamaged skin was removed, and the subcutaneous tissue was removed. After washing, they were respectively fixed at the release port of the Franz diffusion cell, and pH 7.4 phosphoric acid was added to the receiving chamber. The buffer is used as a release medium to keep the endothelial layer in close contact with the solution. Put the cataplasm with the protective layer removed on the skin, adjust the water bath so that the temperature of the outer layer is constant at (32±0.5)°C, and the stirring spee...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides flurbiprofen cataplasm. The cataplasm is composed of a backing layer, a drug reservoir and a protective layer. The cataplasm is characterized in that the drug reservoir is prepared from the following components in percentage by weight: 0.2%-0.5% of flurbiprofen as an active component, 5%-10% of an oil phase component, 5%-10% of partially neutralized sodium polyacrylate as an aqueous phase component, 15%-20% of glycerol, 0.2%-0.4% of aluminum glycinate, 0.1%-0.3% of sodium calcium edetate, 1%-1.5% of carbomer 934, 1.5%-3% of sodium carboxymethyl cellulose (CMC-Na), 0.05%- 0.1% of a pH adjusting agent and gellan gum, 1%-1.5% of L-glycine, 1%-3% of a filler and the balance of water, wherein the oil phase component is prepared from castor oil and benzyl alcohol, the ratio of castor oil to benzyl alcohol is 1 to (0.08 to 0.12), the aqueous phase component and water form hydrogel, the filler is arranged in the hydrogel dispersedly, and the oil phase component is emulsified and disperses in the hydrogel to form the drug reservoir.

Description

technical field [0001] The present invention relates to flurbiprofen cataplasm. Background technique [0002] Flurbiprofen (CAS: 51543-40-9, flurbiprofen) Flurbiprofen is a fluorine-containing non-steroidal anti-inflammatory drug used for the treatment of rheumatoid arthritis and osteoarthritis. However, when the traditional oral administration method is used to treat pain caused by trauma and inflammation of joints, soft tissues, and muscles, it needs to take a large amount of medicine, resulting in relatively large side effects, and the drug release cannot be controlled, making it difficult to provide lasting and effective analgesia on the affected area. Anti-inflammatory effect. Although the use of external preparations can reduce the side effects of oral administration and accelerate the speed of drug onset. However, the traditional external application method has the technical effect of continuous quantitative administration. Compared with conventional external prepa...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/70A61K31/192A61K47/36A61K47/18A61K47/10A61K47/44A61P29/00A61P19/02
Inventor 蔡志浩
Owner 北京茗泽中和药物研究有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com